InterVene Inc. is involved in addressing Chronic Venous Insufficiency (CVI), providing treatment options that include lifestyle modifications, compression therapy, and medications, with a focus on managing chronic venous flow obstruction and its complications.

InterVene, Inc.

InterVene Inc.

InterVene, Inc. | 1,341 followers on LinkedIn. Developing interventional technologies to treat and prevent severe, complex venous diseases | InterVene Inc. is a medical device company developing interventional technologies to treat and prevent chronic venous insufficiency (CVI) with a focus on deep veins and severe, complex venous diseases.
 
The company’s Recana™ thrombectomy catheter system is designed to recanalize chronically obstructed deep veins and to facilitate treatment of in-stent restenosis, particularly in cases where recanalization options are limited or long-term stent maintenance is required. Recana is an investigational device limited by Federal (US) law to investigational use.

Abha Chinubhai

President, Sonoma Medical Consultants

Mel Schatz

Co-Founder/CEO, Throne: Revolutionizing public bathrooms

Fletcher Wilson

Abraham A Van Scoit

InterVene, Inc. is excited to join a select group of medical device companies presenting innovative technologies at #TheVEINS24 Innovation Summit in Las Vegas this Sunday (11/3/2024). Kush Desai , MD will present InterVene's #Recana (formerly Chronus) system, currently in development for recanalizing chronic and postthrombotic (PT) venous occlusion and obstruction. Recana's design facilitates treatment in cases of chronic in-stent restenosis (ISR) and late percutaneous mechanical thrombectomy (PMT) for chronic tissue and obstructed and occluded venous stents. Dr. Desai takes the stage from 7:22-7:33 am during the Blue Sky Breakfast. Hope to see you there! #VIVA24 #chronicvenousinsufficiency #CVI #deepvenousstenting #deepveinthrombosis #DVT Jeff Elkins Catherine Matthes Jay Schmelter Andrew Kleiboeker

INTE

COM:INTERVENE-MED

InterVene Inc.

locale

market

industry

website

crunchbase

linkedin

investor of

Metrics